Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction

PHASE4CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

September 29, 2022

Study Completion Date

September 29, 2022

Conditions
COVID-19Vaccine ReactionImmunization; Infection
Interventions
BIOLOGICAL

Tozinameran

Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Trial Locations (1)

3052

Melbourne Children's campus, Parkville

All Listed Sponsors
lead

Murdoch Childrens Research Institute

OTHER